Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Pluristem Therapeutics, Inc. (PSTI : NSDQ)
 
 • Company Description   
PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells.

Number of Employees: 162

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.50 Daily Weekly Monthly
20 Day Moving Average: 88,701 shares
Shares Outstanding: 32.35 (millions)
Market Capitalization: $48.52 (millions)
Beta: 1.99
52 Week High: $4.55
52 Week Low: $1.31
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -20.64% -10.62%
12 Week -10.18% -1.26%
Year To Date 2.74% 28.04%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5
-
HAIFA,L3 3508409
ISR
ph: 972-74-710-8600
fax: 972-74-710-8787
investor.relations@pluristem.com http://www.pluristem.com
 
 • General Corporate Information   
Officers
Yaky Yanay - Chief Executive Officer and President
Zami Aberman - Executive Chairman
Chen Franco-Yehuda - Chief Financial Officer; Treasurer and Secretary
Mark Germain - Director
Doron Birger - Director

Peer Information
Pluristem Therapeutics, Inc. (CORR.)
Pluristem Therapeutics, Inc. (RSPI)
Pluristem Therapeutics, Inc. (CGXP)
Pluristem Therapeutics, Inc. (BGEN)
Pluristem Therapeutics, Inc. (GTBP)
Pluristem Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 72940R300
SIC: 2836
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 09/12/22
Share - Related Items
Shares Outstanding: 32.35
Most Recent Split Date: 7.00 (0.10:1)
Beta: 1.99
Market Capitalization: $48.52 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.86 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/12/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.21
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 35.42%
vs. Previous Quarter: 8.82%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -100.63
12/31/21 - -95.68
09/30/21 - -98.09
ROA
03/31/22 - -55.46
12/31/21 - -60.65
09/30/21 - -68.42
Current Ratio
03/31/22 - 8.22
12/31/21 - 6.27
09/30/21 - 6.06
Quick Ratio
03/31/22 - 8.22
12/31/21 - 6.27
09/30/21 - 6.06
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -20,024.79
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 1.24
12/31/21 - 1.24
09/30/21 - 1.53
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.57
12/31/21 - 0.58
09/30/21 - 0.48
Debt-to-Capital
03/31/22 - 36.35
12/31/21 - 36.76
09/30/21 - 32.40
 

Powered by Zacks Investment Research ©